Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 38 analyst ratings
Buy
Strong Buy 32%
Buy 45%
Hold 16%
Sell 0%
Strong Sell 8%

Bulls say

Insulet demonstrated robust growth with global Omnipod sales increasing 26% year-over-year on an underlying basis in Q4'24, contributing to total annual sales of $2.07 billion, which reflects a 22% increase year-over-year adjusted for foreign exchange. The company achieved a significant milestone by surpassing 500,000 active global customers, showcasing its strong market presence and adoption rates, particularly in the U.S. where over 85% of new users transitioned from multiple daily injections (MDI). Furthermore, Insulet's innovative integration with smartphones enhances its competitive edge, positioning the Omnipod 5 for continued market share growth against competitors like Medtronic and Tandem.

Bears say

Insulet's operating margins have declined by 240 basis points year-over-year while experiencing only a modest sequential improvement, indicating potential challenges in cost management and profitability. The company's guidance suggests a total sales growth of 16-20%, which is below prior expectations, primarily due to anticipated significant declines in Drug Delivery revenue of 45-55%. Additionally, Insulet's reliance on third-party distribution channels raises operational risks, and heightened competition in diabetes treatment could threaten its customer base and revenue stability moving forward.

Insulet (PODD) has been analyzed by 38 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 45% recommend Buy, 16% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 38 analysts, Insulet (PODD) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $216.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $216.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.